Comirnaty Omicron XBB.1.5 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic use (Phase IV)
COVID-19 vaccine immunological studies in Finland
This study in Finland is looking at how well different COVID-19 vaccines protect people. It's especially interested in how strong our body's defence (antibodies) is six months after two vaccine doses, and how this works against current virus types.
For: COVID-19 infectionFinland - AuthorisedTherapeutic use (Phase IV)
LONGITUDINAL FOLLOW-UP OF SARS-COV-2 IMMUNITY IN IMMUNOCOMPROMISED POPULATIONS IN BELGIUM (COVICO) A non-commercial multicenter academic prospective cohort study during 2023-2026
This study looks at how well COVID-19 vaccines boost immunity in people with weakened immune systems and healthy individuals in Belgium. Researchers will check antibody levels three times a year to understand protection against new virus variants. It aims to help us better protect vulnerable groups.
For: Healthy persons and immunocompromised patients (nursing home residents · dialysis patients and kidney- and lung transplant patients) from age 18 till age 105Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, open-label, randomized, controlled study to evaluate the immune response, safety and reactogenicity of RSVPreF3 OA investigational vaccine when co-administered with a COVID-19 mRNA vaccine (Omicron XBB.1.5) in adults aged 50 years and above.
This study is looking at a new vaccine for RSV (a common cold-like virus) in people aged 50 and over. It's testing if it works well and is safe when given at the same time as an updated COVID-19 vaccine.
For: Respiratory Syncytial Virus InfectionsSpain · Belgium · Netherlands